ABSTRACT. Pseudohypoparathyroidism (PsH) is a genetic disease characterized by hypocalcemia, hyperphosphatemia, and metabolic unresponsiveness to parathyroid hormone (PTH). The administration of PTH elicits neither a significant rise in serum calcium (calcemic response) nor a decrease in the renal tubule reabsorption of phosphorus (phosphaturic response). The diminished phosphaturic response is due to an inability of PTH to generate cyclic AMP in renal tubule cells. We investigated the question of whether hypocalcemia and deficient calcemic response to PTH are due to a similar cyclic AMP defect in bone or to an acquired vitamin D deficiency.
Four patients were studied. The active form of vitamin D (1,25-dihydroxycholecaIciferol) was measured in 3 and was low. Treatment with vitamin D 2 restored the serum calcium and the calcemic response to PTH to normal without changing the impaired renal response. Bone biopsy was performed in 2 patients and showed morphologic evidence of increased osteoclastic activity and osteomalacia. The data indicate that the hypocalcemia and bone disease in PsH are due to active vitamin D deficiency, possibly resulting from the genetic renal lesion.
(J Clin Endocrinol Metab 42: 621, 1976) P SEUDOHYPOPARATHYROIDISM (PsH) is a disorder characterized by hypocalcemia, hyperphosphatemia, and deficient calcemic and phosphaturic responses to exogenously administered parathyroid hormone (PTH). These data suggest that the disorder is due to end-organ unresponsiveness to PTH, and this has been confinned by measurements indicating that serum PTH is markedly elevated. Chase et al. (1) have shown that PTH action on the kidney is mediated through an increase in renal cyclic adenosine 3',5'-monophosphate (cyclic AMP). In PsH the urine cylcic AMP response to exogenous PTH is markedly diminished, consistent with renal refractoriness to PTH. Evidence that bone cells are also innately unresponsive to PTH has been largely from inference, based on the systemic hypocalcemia and a subnormal rise in serum calcium when PTH is given to patients with PsH. We have investigated the question of whether calcemic unresponsiveness in PsH might be an acquired lesion or due to disordered vitamin D metabolism in PsH.
Materials and Methods
Four patients (32, 29, 45 , and 32 years old) with PsH were hospitalized in the Duke University Medical Center Clinical Research Unit. Informed consent was obtained for all studies. The patients received a diet containing 1200 mg of phosphorus and 900 mg of calcium/day. Studies requiring hourly urine determinations were preceded by a water load (20 mg/kg), and urine was collected by spontaneous voiding at designated intervals. Bovine parathyroid extract for parenteral use (Eli Lilly Co.) was of proven activity.
SePim calcium, phosphorus, alkaline phosphatase, and creatinine were determined on the multichannel Technicon AutoAnalyzer. Serum magnesium was measured by the method of Thiers (2) . Serum parathyroid hormone assays were performed in the laboratories of Dr. Claude 4), and the data are presented as the mean of triplicate determinations of a single blood specimen. Urine specimens were stored at -20 C before determination of cyclic AMP (8) , phosphorus (9) , and creatinine (10) . The tubular maximum for reabsorption of phosphate, normalized to glomerular filtration rate (T m /GFR), was calculated by the method of Bijvoet (11) .
Fat was measured in 72 hour fecal collections by the method of Van de Kamer (12) . Urinary d-xylose was measured (13) in 5 hour urine specimens after the ingestion of 25 gm of d-xylose. Calcium absorption was calculated by measurement (14) of dietary calcium intake minus fecal calcium excretion, over a 5 day period.
Special studies were undertaken in two patients (Cases 1 and 2). Under general anesthesia, the right anterior iliac crest was biopsied and specimens were preserved in 70% alcohol. Dr. Jennifer Jowsey assessed morphology and performed quantitative analysis on these undecalcified specimens according to methods previously described (15, 16) .
Results

The Diagnosis of pseudohypoparathyroidism
All four patients had hypocalcemia and hyperphosphatemia (Table 1) , and Cases 2 and 3 showed the typical skeletal abnormalities of PsH described by Albright et al. (17) . In addition, all showed the markedly blunted increase in urine cyclic AMP excretion in response to parathyroid extract that is the single best criterion for establishing the diagnosis of PsH (1) . These data imply renal unresponsiveness to PTH action. This was confirmed by finding an elevated (>4.8 in all cases) theoretical tubular maximum for the reabsorption of phosphate per liter of glomerular filtrate (T m /GFR) and, where tested (Cases 1, 2, and 3), an insignificant fall in T^GFR (A T m /GFR in Table 1 ) in response to bovine parathyroid extract. Calcium dynamics and bone metabolism in pseudohypoparathyroidism All our patients had hypocalcemia; all had normal serum magnesium concentrations (2.0, 1.8, 2.1, 2.0 meq/1 [normal range: 1.7-2.2 meq/1]) and all could acidify urine maximally. The serum PTH concentrations were increased (Table 1 ). These observations suggest that our patients lacked bone responsiveness to PTH. The administration of bovine parathyroid extract appeared to confirm this inference. In response to 200 U of parathyroid extract given intramuscularly every 6 hours for 72 hours, the patients showed a diminished calcemic response (Table 1 ; Fig. 1 in serum calcium of < 1.0 mg/dl to diagnose PsH). However, two of our patients (Cases 2 and 3) had radiographic evidence of bone demineralization and one (Case 1) had radiographic changes of osteitis fibrosa cystica. We therefore performed iliac crest biopsies on two patients (Cases 1 and 2) . In Case 1, sections from the biopsy showed areas of active bone resorption and osteitis fibrosa cystica, as well as widened osteoid seams (Fig. 2) . The bony cortexes and trabeculae were thin, and the calcification fronts abnormal, being either absent or broad and diffuse. Quantitative analysis (Table 2) confirmed these observations. The bone biopsy from Case 2 likewise showed increased bone resorption and widened osteoid seams (Table 2) . However, the assessment of calcification fronts and the surface area of the bone covered by unmineralized osteoid tissue was precluded by a period of bed rest (10 days) before biopsy which resulted in decreased bone formation (19) . These results are indicative of increased PTH action on bone. In addition, the widened osteoid seams, as well as the abnormal calcification fronts in Case 1, are compatible with osteomalacia. Serum alkaline phosphatase activity (bone isoenzyme) was increased in Cases 1, 2, and 4, lending further evidence of increased bone turnover.
Vitamin D metabolism in pseudohypoparathyroidism
There was no evidence in the patients' histories to suggest dietary insufficiency of vitamin D. Fecal fat excretion and d-xylose absorption ruled out malabsorption in the three patients studied (Cases 1, 2, and 4). Since, in man, vitamin D (cholecalciferol) must be activated by hydroxylation to 25- hydroxy-cholecalciferol (25-HCC) and subsequently further hydroxylated to 1,25-dihydroxy-cholecalciferol (1,25-DHCC) (20), we measured the concentrations of these products in several patients. The 25-HCC concentration was normal in three subjects (Cases 1, 2, and 3) and marginally elevated in Case 4, a patient for whom vitamin D had previously been prescribed (see Table  1 ). Plasma 1,25-DHCC concentration was, however, low in the three subjects studied (Cases 1, 2, and 4) ( 
Treatment with ergo calciferol restores calcemic response
It has long been known that dietary vitamin D deficiency (rickets) creates a state of calcemic unresponsiveness to PTH (22) . If the calcemic unresponsiveness in PsH is secondary to 1,25-DHCC deficiency, then treatment with large amounts of ergocalciferol or dihydrotachysterol might be sufficient to repair the deficit in active vitamin D. Accordingly, we treated our patients with sufficient ergocalciferol (50-100,000 U/ day) to raise serum calcium into the normal range. The time elapsed from the initiation of therapy to the attainment of a normal serum calcium, and subsequent retesting, ranged from 2 weeks (Cases 1, 2, and 4) to one year (Case 3). Table 1 shows that ergocalciferol therapy raised plasma calcium and lowered plasma phosphorus in all four patients. There was no change in renal phosphaturic or cyclic AMP response to intravenous parathyroid extract (Table 1) . However, the calcium response to intramuscular parathyroid extract was markedly enhanced (Table 1 and Figure 1 ). In every case the increment in serum calcium in response to a single dose of parathyroid extract (200 U im) was 1.9 mg/dl or greater and the response occurred by 8 hours after administration. In each individual the actual serum calcium concentration rose to 10.8 mg/dl or greater, and, therefore, only a single dose of parathyroid extract could safely be administered. To demonstrate that the restoration of the calcemic response was not simply a result of the raised serum calcium concentration found in treated patients, we infused calcium (prior to treatment with ergocalciferol) in two subjects (Cases 1 and 2 ). When serum calcium had reached steady concentrations, greater than 10 mg/dl in both patients and serum immunoreactive PTH, measured by amino terminal assay, was suppressed (data not shown), we gave a single dose of 200 U of parathyroid extract by intramuscular injection. In both cases the impaired rise in serum calcium (<0.8 mg/dl) persisted.
Discussion
Since Albright et al. (17) first described PsH it has been recognized that renal unresponsiveness to PTH is the hallmark of this disease. A vigorous and continuing effort has characterized the biochemical defect at this organ (1, 23) , and our patients satisfy the criteria of renal unresponsiveness. It is, furthermore, undoubted that patients with PsH have a diminished calcemic response to intramuscular PTH (18) . Again, our patients satisfy this criterion. Nevertheless, 20% of the patients with PsH reported by Bronsky et al. (24) had radiographic evidence of osteopenia. Bone biopsies of 7 previously reported patients (25) (26) (27) with PsH have shown evidence of increased bone turnover, with or without widened osteoid seams, and 10 patients have been reported to have radiographic evidence of osteitis fibrosa cystica (28, 34) . It has been difficult to reconcile these observations, as well as the occasional finding of normocalcemia in PsH (35) , with the supposition that the bone cells in this disorder are intrinsically incapable of responding to PTH.
The possibility that the calcemic unresponsiveness is secondary to some renal lesion has been entertained previously. Rasmussen (36) outlined a mechanism which postulated osteitis fibrosa cystica and subsequent calcemic unresponsiveness due to hyperphosphatemia, and Frame (37) theorized that disordered Vitamin D metabolism might be involved. Our data demonstrate bone changes (and calcemic unresponsiveness) consistent with impaired vitamin D metabolism and studies in Case 1 showed impaired absorption of calcium, corrected by vitamin D treatment. Although it is not known precisely how the kidney controls the enzymatic hydroxylation of precursor 25-HCC to the active product 1,25-DHCC, PTH (perhaps mediated by cyclic AMP, or a decrease in renal cell phosphate concentration, or both) appears to enhance 1-hydroxylation of 25-HCC (38) . Individuals with PsH have two factors possibly impairing activation of vitamin D: they cannot generate renal cyclic AMP in response to PTH, and they have elevated plasma phosphorus. In any case, they have subnormal serum concentration of 1,25-DHCC consistent with an ineffective synthesis of 1,25-DHCC.
All our patients with PsH have acquired calcemic unresponsiveness to PTH, shown by the restoration of this responsiveness following treatment with therapeutic doses of ergocalciferol (Table 1) . Studies of patients with nutritional vitamin D deficiency rickets (22) and of animals with induced vitamin D deficiency (39) , have demonstrated that active vitamin D metabolites are required for PTH to elicit a calcemic response. The cause of the absent calcemic response to PTH in vitamin D deficiency states has been extensively studied, but the mechanism remains unclear. The major conclusion from both animal and human studies is that in vitamin D deficiency, in spite of clear evidence of hyperparathyroidism, there is failure to mobilize sufficient calcium from bone to maintain calcium homeostasis. The major identifiable defect in the bone appears to be a failure of osteoclastic maturation or differentiation (39) . In PsH there is both increased PTH and decreased 1,25-DHCC concentrations, and the lack of a calcemic response to PTH is therefore expected. The absence of a similar defect in patients with idiopathic or surgical hypoparathyroidism, despite similar depressed concentrations of 1,25-DHCC (unpublished observations) has been noted. However, the loss of the calcemic response to PTH has thus far been associated only with conditions in which endogenous PTH concentration is increased and 1,25-DHCC concentration decreased {e.g., vitamin D deficiency rickets; renal failure). Thus, loss of calcemic response appears secondary to the chronic effects of increased endogenous PTH on bone turnover and bone cell activity, coupled with active vitamin D deficiency. The absence of an elevated concentration of endogenous PTH in idiopathic and surgical hypoparathyroidism may therefore preserve calcemic responsiveness. It is reasonable to suggest, however, that the absent osseous response to PTH may be secondary to sustained hypocalcemia. Indeed longterm treatment with calcium sufficient to maintain normocalcemia might suppress PTH and its effects on bone turnover, resulting in the laying down of new calcification fronts in bone and the restoration of calcemic responsiveness (40) . It was not possible to perform such studies in this investigation.
We envisage the sequence of metabolic events in PsH as follows: a genetic inability of the kidney cells to respond to PTH with a rise in cyclic AMP results in an elevated Tm/GFR and a raised concentration of phosphorus in plasma. Furthermore, the kidney is unable to convert 25-HCC to 1,25-DHCC. The lack of active vitamin D3 results, eventually, in calcemic unresponsiveness. In addition, there may be roentgenographic or morphologic evidence of osteomalacia, osteopenia, or osteitis fibrosa cystica depending, perhaps, on the rate of development of the 1,25-DHCC deficiency and the concentration of plasma PTH. (For instance, Case 1 had markedly raised serum PTH concentration and bone changes of osteitis fibrosa cystica). We suspect that treatment with large doses of ergocalciferol produces adequate amounts of an active vitamin D metabolite, either 1,25-dihydroxyergocalciferol or sufficiently large concentrations of 25-hydroxyergocalciferol to elicit the metabolic response (41) . There then follows healing of the bone lesion and restoration of the calcemic response to PTH. Measurement of 1,25-dihydroxyergocalciferol is not presently available, however, and post-treatment 25-hydroxyergocalciferol levels were not obtained. Therefore, the precise mechanism by which calcemic responsiveness returns to normal remains unknown. Nevertheless, the bony defect appears to be acquired and secondary to decreased 1,25-DHCC.
